Halozyme Therapeutics, Inc.
HALO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001159036
In the last 90 days, Halozyme Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 674 institutions reported holding it in 13F filings for Q2 2026, worth $9.62B in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Halozyme Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 370 | 2 | 390 | +22 |
| Shares | 123.3M | 24.0K | 123.2M | −91.1K (−0.1%) |
| Value | $4.45B | $865.4K | $4.71B | +$257.9M (+5.8%) |
2 institutions that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (51)
Institutions that held Halozyme Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
Sold out (29)
Institutions that held Halozyme Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
Not filed for Q3 2023 yet (2)
Institutions that held Halozyme Therapeutics, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Pictet Asset Management SA | 15,982 | $576.5K |
| Efg Capital International Corp. | 8,009 | $288.9K |